Emory Childrens Center — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$1,413	3
2024	Research	$2,081	2
2022	Research	$17,051	2
2021	Research	$34,211	4
2020	Research	$3,394	4
2019	Research	$43,368	8

Breakdown

Who paid Research payments · program years 2019–2025

Merck Sharp & Dohme Corporation $60,050 13 payments
Daiichi Sankyo Inc. $35,220 4 payments
Novartis Pharmaceuticals Corporation $2,754 1 payment
Pfizer Inc. $1,413 3 payments
Boehringer Ingelheim Pharmaceuticals, Inc. $1,054 1 payment
Boehringer Ingelheim International GmbH $1,027 1 payment

Studies the money was for Research payments · program years 2019–2025

Wel-A-U307 $35,220 4 payments
A Phase 2 Clinical Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Doravirine and Doravirine,Lamivudine,Tenofovir Disoproxil Fumarate in Participants With HIV-1, who are 4 Weeks to less than 12 Years of Age and Weigh less than 45 kg $34,975 4 payments
A Phase 2 Clinical Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Doravirine,Islatravir in Pediatric Participants with HIV-1 Infection who are Virologically Suppressed or Treatment-Na , are Less Than 18 Years of Age, and Weigh Greater Than or Equal to 35 kg $16,287 2 payments
Pediatric Carriage Study $8,184 6 payments
A Non-Interventional Study Collecting Safety Data From Systemic Juvenile Idiopathic Arthritis Sjia Patients Enrolled in the Childhood Arthritis & Rheumatology Research Alliance Carra Disease Registry Who Initiate Treatment With Canakinumab Or Comparator $2,754 1 payment
PoCP study in FSGS $2,081 2 payments
A Phase 3 Protocol to Investigate the Safety Tolerability and Immunogenicity of A Bnt162b2 Lp81adapted Vaccine in Children 5 Through 11 Years of Age Considered at High Risk for Severe Covid19 $1,413 3 payments
A Phase 2 Clinical Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Doravirine,Islatravir in Pediatric Participants with HIV-1 Infection who are Virologically Suppressed or Treatment-Na ve, are Less Than 18 Years of Age, and Weigh Greater Than or Equal to 35 kg $604 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.